1
Clinical Trials associated with 64Cu-DOTA-TLX592A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592). TLX592 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours, therefore this study has been designed to assess the safety and tolerability, pharmacokinetics, whole body biodistribution and radiation dosimetry of 64Cu-TLX592.
Start Date04 Aug 2021 |
Sponsor / Collaborator- |
100 Clinical Results associated with 64Cu-DOTA-TLX592
100 Translational Medicine associated with 64Cu-DOTA-TLX592
100 Patents (Medical) associated with 64Cu-DOTA-TLX592
100 Deals associated with 64Cu-DOTA-TLX592